Prostate cancer and prostatic diseases
Journal
Overview
publication venue for
-
Predictors of fluoroquinolone-resistant bacterial colonization prior to prostate biopsy: a secondary analysis of two randomized trials.
2026
-
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).
2026
-
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.
2026
-
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.
2025
-
Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.
2025
-
Ultrasound echogenicity is complementary to PI-RADS for risk stratification of clinically significant prostate cancer.
2025
-
Racial variation in the advanced prostate cancer genome..
28.
2025
-
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study..
28.
2024
-
Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality..
28.
2024
-
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab..
28.
2024
-
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board..
28.
2024
-
External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension..
27.
2023
-
Characteristics of incidental prostate cancer in the United States..
27.
2023
-
Impact of persistent PSA after salvage radical prostatectomy: a multicenter study..
27.
2023
-
Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate..
27.
2023
-
Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States..
26.
2022
-
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)..
25.
2022
-
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score..
25.
2022
-
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials..
25.
2021
-
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate..
24.
2021
-
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer..
24.
2021
-
Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI)..
24.
2020
-
Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States..
23.
2020
-
Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis..
24.
2020
-
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer..
23.
2020
-
Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy..
23.
2020
-
Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia..
23.
2019
-
Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies..
23.
2019
-
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram..
21.
2018
-
Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study..
21.
2018
-
Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy..
21.
2017
-
Molecular alterations in prostate cancer and association with MRI features..
20.
2017
-
Periprostatic adipose inflammation is associated with high-grade prostate cancer..
20.
2017
-
Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy..
20.
2017
-
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL..
20.
2017
-
Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study..
20.
2017
-
Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy..
20.
2016
-
Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease..
19.
2016
-
Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy..
19.
2016
-
The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy..
19.
2016
-
In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI..
19.
2016
-
Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection..
19.
2015
-
Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension..
18.
2015
-
The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices..
18.
2014
-
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act..
17.
2014
-
Androgen dynamics and serum PSA in patients treated with abiraterone acetate..
17.
2014
-
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer..
17.
2013
-
Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy..
16.
2013
-
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer..
16.
2013
-
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer..
13.
2010
-
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis..
11.
2007
-
Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy..
7.
2004
-
Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible..
6.
2003
-
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen..
5.
2002
-
The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer..
5.
2002
-
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer..
4.
2001
-
The impact of sexual and urinary dysfunction on health-related quality-of-life (HRQOL) following radical prostatectomy (RP)..
3.
2000
-
Clinical and pathologic significance of T1c adenocarcinoma of the prostate cancer..
2.
1999
-
Editorial..
2.
1999
-
Editorial..
2.
1999
-
Editorial..
2.
1999
-
Pathologic progression of autochthonous prostate cancer in the TRAMP model..
2.
1999
-
The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells..
2.
1999
-
Editorial..
1.
1998
-
Unravelling the confusions in prostatic disease..
1.
1998
-
Editorial..
1.
1997
-
Editorial..
1.
1997
-
Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen..
1.
1997
-
Publisher Correction: Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis..
28.
2025
-
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis..
26.
2023
-
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate..
25.
2022
-
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate..
25.
2022
-
Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer..
24.
2021
-
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists..
12.
2008
-
Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.
2026
-
Identifying the best candidate for focal therapy: a comprehensive review.
2024
-
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).
2024
-
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2).
2024
-
Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis.
2024
-
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis.
2024
-
Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis.
2024
-
Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis.
2024
-
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer.
2024
-
Artificial intelligence applications in prostate cancer.
2023
-
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
2022
-
Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes.
2022
-
Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis.
2022
-
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
2021
-
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
2021
-
Clinical considerations for the management of androgen indifferent prostate cancer.
2021
-
Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.
2020
-
Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis.
2019
-
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.
2017
-
The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients.
2016
-
The very-high-risk prostate cancer: a contemporary update.
2016
-
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
2009
-
New circulating biomarkers for prostate cancer.
2007
-
Photoselective vaporization of the prostate (GreenLight PV): lessons learnt after 3500 procedures.
2007
-
The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
2005
Identity
ISO Abbreviation
-
Prostate Cancer Prostatic Dis
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)